FDA's Guide: How We Peek into Your Lipstick Lab Records
Published Date: 1/22/2026
Notice
Summary
The FDA just dropped a draft guide to help cosmetic companies understand how the agency can check their product records. If you make or sell cosmetics, this guide explains what info the FDA might ask for and how the process works. You’ve got until March 23, 2026, to share your thoughts before the FDA finalizes the rules—no extra costs yet, just clear steps ahead!
Analyzed Economic Effects
4 provisions identified: 1 benefits, 3 costs, 0 mixed.
FDA can copy records if SAHCODH suspected
Under section 610 (21 U.S.C. 364f), if FDA reasonably believes a cosmetic (or an ingredient) is likely adulterated and presents a threat of serious adverse health consequences or death (SAHCODH), FDA may access and copy certain records. The draft guidance explains how FDA applies that authority and what records may be copied.
Inspection authority extended to manufacturer records
Section 704(a)(1) of the FD&C Act, as amended by MoCRA (section 3504), extends FDA's inspectional authority to all records and information described in sections 605 and 610 from facilities that manufacture and process cosmetic products. The draft guidance discusses how that expanded inspection authority is applied.
FDA access to adverse event records
If you make or sell cosmetics, FDA can access adverse event records during an inspection under section 605 (21 U.S.C. 364a) and section 704 of the FD&C Act. The draft guidance explains FDA's criteria, process, and expectations for that access.
Draft guidance available — comment deadline
The FDA released a draft guidance titled "FDA Records Access Authority for Cosmetics: Guidance for Industry" and is asking for comments. You may submit electronic or written comments by March 23, 2026; the guidance is not binding and explains FDA's current thinking on criteria, process, and expectations.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-01158 — Medical Review Board; Membership
The Department of Transportation is looking for new members to join the Medical Review Board, which gives expert medical advice about truck driver health rules. If you or someone you know works in medicine and wants to help shape safety standards for commercial drivers, now’s the time to apply! Nominations are due by February 23, 2026, and there’s no cost to join—just a chance to make a big impact.
Next: 2026-01160 — Procurement List; Additions
Starting February 1, 2026, new services will be added to the government’s Procurement List, meaning federal agencies must buy these services from nonprofit groups that employ people who are blind or have severe disabilities. This change helps support these nonprofits without adding extra paperwork or costs. It’s a win-win for the government and amazing workers making a difference!